<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8B52962918F74F66A4B3C6D28FE0C8E6" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 3810 IH: Drug Origin Transparency Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3810</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230605">June 5, 2023</action-date><action-desc><sponsor name-id="E000215">Ms. Eshoo</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.</official-title></form><legis-body id="H71E2570F38AE4AB994E721255B81261A" style="OLC"><section id="H4DB801853EC1466EA007465D5CFFE0E9" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Drug Origin Transparency Act of 2023</short-title></quote>. </text></section><section id="H8B0B8B9EC8EC4166BF9F586A4C141CBA"><enum>2.</enum><header>Enhanced drug manufacturing amount information reporting</header><subsection id="H20459A193B1C47F3ADFCD10EE38DE75B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(j)(3)</external-xref>) is amended—</text><paragraph id="H859E91313D014FDFA8BE2C62BA94C406"><enum>(1)</enum><text>in subparagraph (A), by adding <quote>or (2)</quote> after <quote>paragraph (1)</quote>; and</text></paragraph><paragraph id="HC014BE1A3B3C44D9990343D3EABD1458"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text><quoted-block style="OLC" id="H006A2B5B5FA141A4B8C2470F256775B1" display-inline="no-display-inline"><subparagraph id="H4410298375EB4ED09D59EAC2DC645644" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">Each report submitted pursuant to subparagraph (A) with respect to a drug shall—</text><clause id="H552E9506E6AB46868F4AD8EB65210DD2"><enum>(i)</enum><text>include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—</text><subclause id="H3426AD692233474090A69B3BFB2A2AB9"><enum>(I)</enum><text>the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and</text></subclause><subclause id="H9A56A1D3174E44F49590D8C9D74FAF8E"><enum>(II)</enum><text display-inline="yes-display-inline">the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material from each such identified supplier; and</text></subclause></clause><clause id="HC4E93A732A364EDDA65D1B3547AD9BDE"><enum>(ii)</enum><text>be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year.</text></clause></subparagraph><subparagraph id="HADA338AB44734D399BE2602EF29A2946" indent="up1"><enum>(D)</enum><text>Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H60910289CFBD4187BB52B7769D621FAF"><enum>(b)</enum><header>Conforming amendment</header><text>Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/510">21 U.S.C. 510(j)(3)(B)</external-xref>) is amended by striking <quote>subparagraph (A)</quote> and inserting <quote>this paragraph</quote>.</text></subsection></section><section id="H76F1152EEEBE4E0AA13B169362FC77C5"><enum>3.</enum><header>Require drug labeling to include original manufacturer and supply chain information</header><text display-inline="no-display-inline">Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended—</text><paragraph id="H89C22C1EFF584E37884DD72D290D8EB4"><enum>(1)</enum><text>in paragraph (b)—</text><subparagraph id="H85822B6D5FFC4AAE894F8AD52FFC52C9"><enum>(A)</enum><text>by striking <quote>(b) If in a package</quote> and inserting <quote>(b)(1) If in a package</quote>;</text></subparagraph><subparagraph id="HB917AD0A612F416F866D3EF0166DA36F"><enum>(B)</enum><text>by striking <quote>a label containing (1) the name and place</quote> and inserting </text><quoted-block style="OLC" id="H13B8438F4E2646D28DB9D017D2CC210B" display-inline="yes-display-inline"><text>a label containing—</text><paragraph id="H02CBB35BA4C045C1AECF52209660CCBA"><enum>(A)</enum><text display-inline="yes-display-inline">the name and place</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph><subparagraph id="H9846738954DD443D9144295205F87520"><enum>(C)</enum><text display-inline="yes-display-inline">by striking <quote>or distributor; and (2) an accurate statement</quote> and inserting </text><quoted-block style="OLC" id="HD5188F1D7E054F4D901DFDBB6E0CFB80" display-inline="yes-display-inline"><text>or distributor; and </text><paragraph id="H6BA577F64BBD420DB375BA4686058EEA"><enum>(B)</enum><text display-inline="yes-display-inline">an accurate statement</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph><subparagraph id="H3371B34996EE4F78A20006AA0B6D1469"><enum>(D)</enum><text>by striking <quote>under clause (2) of this paragraph</quote> and inserting <quote>under this clause</quote>; and</text></subparagraph><subparagraph id="HCDD030F2EED542D8A0A8F199FD5EA644"><enum>(E)</enum><text>by inserting at the end the following:</text><quoted-block id="H0C605C790D604CB19EC6516F348760DB" style="OLC"><paragraph id="HED3CD839FA3142E9A52A143B1ABE3326"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H359372924B7348DC95B6BD76737A5DCC"><enum>(A)</enum><text display-inline="yes-display-inline">Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements.</text></subparagraph><subparagraph id="H2BC63DB4F5EC471B924CD2AF2F96F1D2" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying<italic></italic> certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient.</text></subparagraph><subparagraph id="H101B184CC2EF45BE97A202F78F1AC09C" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H3413CBB2EBB94152A78878E4302D832D"><enum>(2)</enum><text>by inserting after paragraph (c) the following:</text><quoted-block id="HFA564CB8471A44D3A4ABC893A894264E" style="OLC"><subsection id="H8C9F6AB37BA44B52BCC5245460FCF2EE"><enum>(d)</enum><paragraph commented="no" display-inline="yes-display-inline" id="HCDA07B6D893C47A0BC0726B8BEAC41F3"><enum>(1)</enum><text>Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of—</text><subparagraph id="HB98A361ECDA24A80B4968865B5EA25FE" indent="up1"><enum>(A)</enum><text>the original manufacturer of each active pharmaceutical ingredient;</text></subparagraph><subparagraph id="H342C8D860C6142C18097C41EA41EE1AD" indent="up1"><enum>(B)</enum><text>each manufacturer, if different from the original manufacturer; and</text></subparagraph><subparagraph id="H1100818ACA6142B18C877D43D355B479" indent="up1"><enum>(C)</enum><text>the packer or distributor, if any.</text></subparagraph></paragraph><paragraph id="HA6E2D00CBF414810976991162D69077A" indent="up1"><enum>(2)</enum><text>The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

